document

Hybrid Semantic Mapping for Autonomous Off-Road Driving. MSC thesis Delft University

Bos, R. (author)

report 2022

document

Acoustic ranging with communication signals for wireless diver guidance to base

Dol, H.S. (author), van den Bos, R. (author)

There are situations in which divers need to find their way to an unknown location within acoustic communication range as quickly as possible without broadcasting additional energy besides that of already transmitted acoustic communi cation signals, e.g., for acoustic covertness or saving battery life. For these situations, a prototype of a...

conference paper 2020

document

Toward a mechanism-based in vitro safety test for pertussis toxin

Vaessen, S.F. (author), Bruysters, M.W. (author), Vandebriel, R.J. (author), Verkoeijen, S. (author), Bos, R. (author), Krul, C.A.M. (author), Akkermans, A.M. (author)

Pertussis vaccines are routinely administered to infants to protect them from whooping cough. Still, an adequate safety test for pertussis toxin (PT), one of the main antigens in these vaccines, is not available. The histamine sensitization test is currently the only assay accepted by regulatory authorities to test for the absence of active PT...

article 2014

document

Acetazolamide improves cerebral oxygenation during exercise at high altitude

Vuyk, J. (author), van den Bos, J. (author), Terhell, K. (author), de Bos, R. (author), Vletter, A. (author), Valk, P. (author), van Beuzekom, M. (author), van Kleef, J. (author), Dahan, A. (author), TNO Technische Menskunde (author)

Acute mountain sickness is thought to be triggered by cerebral hypoxemia and be prevented by acetazolamide (Actz). The effect of Actz on cerebral oxygenation at altitude remains unknown. In 16 members of the 2005 Dutch Cho Oyu (8201 m, Tibet) expedition, the influence of Actz and exercise (750 mg PO daily) on heart rate, peripheral and regional...

article 2006

document

Factor V antigen levels and venous thrombosis: Risk profile, interaction with factor V leiden, and relation with factor VII antigen levels

Kamphuisen, P.W. (author), Rosendaal, F.R. (author), Eikenboom, J.C.J. (author), Bos, R. (author), Bertina, R.M. (author), Gaubius Instituut TNO (author)

Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the formation of thrombin, whereas anticoagulant factor V acts as a cofactor for activated protein C (APC) in the degradation of factor VIII/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether plasma factor...

article 2000

document

Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia

TNO Preventie en Gezondheid (author), Meijers, J.C.M. (author), Oudijk, E.J.D. (author), Mosnier, L.O. (author), Bos, R. (author), Bouma, B.N. (author), Nieuwenhuis, H.K. (author), Fijnheer, R. (author)

Acute promyelocytic leukaemia (APL) is a disease that is distinguished from other leukaemias by the high potential for early haemorrhagic death. Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between...

article 2000

document

Elastase mediated fibrinolysis in acute promyelocytic leukemia

TNO Preventie en Gezondheid (author), Oudijk, E.J.D. (author), Nieuwenhuis, H.K. (author), Bos, R. (author), Fijnheer, R. (author)

The bleeding syndrome of acute promyelocytic leukemia (APL) is complex and consists of disseminated intravascular coagulation (DIC) and hyperfibrinolysis. Elastase, derived from malignant promyelocytes, is believed to mediate the fibrinogeno- and fibrinolysis by aspecific proteolysis. In this study we measured the role of elastase in fifteen...

article 2000

document

Comparison of tests for the measurement of C-reactive protein in the low range

Bos, R. (author), de Maat, M. (author), Gaubius Instituut TNO (author)

C-reactive protein (CRP) has recently been identified as an independent risk factor for cardiovascular disease. The published studies all used highly sensitive immunological assays that were specially designed in-house to measure CRP in the sub-clinical (normal) range. However, these tests are not commercially available. The aim of the present...

article 1998

document

A new test for measuring soluble fibrin in plasma with a high predictive value for thrombotic disorders

Bos, R. (author), Laterveer, R. (author), Lockwood, D. (author), Szewczyk, K. (author), Nieuwenhuizen, W. (author), TNO Preventie en Gezondheid (author)

Fibrin formation is initiated by thrombin which releases the fibrinopeptides A and B from fibrinogen. In vivo, fibrin molecules form soluble complexes with fibrinogen. At a certain threshold concentration, fibrin-fibrin interactions prevail and insoluble aggregates are formed on site. Soluble fibrin is considered to be an early biochemical...

article 1998

document

An enzyme immunoassay for polymorphonuclear leucocyte-mediated fibrinogenolysis

Bos, R. (author), van Leuven, C.J.M. (author), Stolk, J. (author), Hiemstra, P.S. (author), Ronday, H.K. (author), Nieuwenhuizen, W. (author), TNO Preventie en Gezondheid (author)

Upon stimulation, polymorphonuclear leucocytes (PMNs) release potent serine proteases, i.e. elastase, cathepsin C and proteinase 3, which contribute to the degradation of tissue and plasma components. Here, we describe the development of a plasma test to assess PMN-mediated fibrinogenolysis as a biochemical marker for actual PMN-derived...

article 1997

document

Monoclonal antibodies against the human mannose receptor that inhibit the binding of tissue-type plasminogen activator

Barrett-Bergshoeff, M.M. (author), Moorman, F. (author), Bos, R. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)

To study the role of the mannose receptor in cellular uptake and degradation of tissue-type plasminogen activator (t-PA), a set of five monoclonal antibodies (Moab) was generated against the mannose receptor isolated from human placental tissue. All Moab specifically recognised the 175 kDa mannose receptor in a crude placenta extract, as shown...

article 1997

document

A specific test for polymorphonuclear leukocyte-mediated fibrinogenolysis in plasma

Bos, R. (author), van Leuven, C.J.M. (author), Stolk, J. (author), Hiemstra, P.S. (author), Ronday, H.K. (author), Dijkman, J.H. (author), Nieuwenhuizen, W. (author), TNO Preventie en Gezondheid (author)

In response to inflammatory mediators, polymorphonuclear leukocytes (PMN) are activated and release potent serine proteases, i.e. elastase, cathepsin G and proteinase 3. The aim of this study was to develop an assay to determine PMNmediated fibrinogenolysis in plasma, as a biochemical marker for activated PMN in vivo. On the basis of a special...

article 1996

document

A bio-immuno assay to determine free tissue-type plasminogen activator (t-PA) in Stabilyte® plasma

Bos, R. (author), Revet, M. (author), Nieuwenhuizen, W. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)

This article describes a two-step bio-immuno assay (BIA), which determines active (free) tissue-type plasminogen activator (t-PA) in (acidified) plasma. Plasma samples, diluted in buffer of pH 6.0, are added to the wells of a microtiter plate containing an immobilised monoclonal antibody which binds t-PA without affecting t-PA activity. After an...

article 1994

document

Bispecific monoclonal antiboldies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)

Bos, R. (author), Nieuwenhuizen, W. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)

article 1992

document

Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA

Otter, M. (author), Kuiper, J. (author), Bos, R. (author), Rijken, D.C. (author), van Berkel, T.J.C. (author), Gaubius Laboratory Instituut voor verouderings- en vaatziekten onderzoek TNO (author)

The interaction of 125I-labelled tissue-type plasminogen activator (125I-t-PA) with freshly isolated rat parenchymal and endothelial liver cells was studied. Binding experiments at 4°C with parenchymal cells and endothelial liver cells indicated the presence of 68000 and 44000 high-affinity t-PA-binding sites, with an apparent K(d) of 3.5 and 4...

article 1992

document

Production and applications of mono- and bispecific monoclonal antibodies for fibrinolysis studies

Gaubius instituut Instituut voor verouderings- en vaatziekten onderzoek TNO (author), Bos, R. (author)

doctoral thesis 1992

document

One-step purification of tissue-type plasminogen activator using affintiy chromatography with a special monoclonal antibody under mild conditions

Gaubius Instituut TNO (author), Bos, R. (author), Berger, L. (author), Nieuwenhuizen, W. (author)

We have previously isolated a monoclonal antibody, designated as 1-3-1, specific for tissue-type plasminogen activator (t-PA). We have shown that t-PA dissociates from 1-3-1 in the presence of the lysine analogue 6-aminohexanoic acid (6-AHA). Here we describe a method for the one-step immunoaffinity purification of t-PA from conditioned melanoma...

article 1992

document

Production and characterisation of a set of monoclonal antibodies against tissue-type plasminogen activator (t-PA)

Gaubius Instituut TNO (author), Bos, R. (author), Siegel, K. (author), Otter, M. (author), Nieuwenhuizen, W. (author)

To generate bispecific monoclonal antibodies, reactive to both fibrin and tissue-type plasminogen activator (t-PA), we planned to generate anti-t-PA monoclonal antibodies (mAb) which eliminate negative aspects of t-PA such as the inhibition by plasminogen activator inhibitor-type 1 (PAI-1) and the rapid clearance of t-PA. Here we report on the...

article 1992

document

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: Why they are used and how they are made

Gaubius instituut TNO Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author), Bos, R. (author), Nieuwenhuizen, W. (author)

The generation of the proteolytic enzyme plasmin from its inactive precursor plasminogen, mediated by so called plasminogen activators, is the essential step in thrombolytic therapy. Plasmin is responsible for the degradation of the insoluble fibrin, the major component of a thrombus, to soluble fibrin degradation products. So far, the use of...

article 1992

document

A method for the transformation of hybridoma cell lines with improved efficiency: Its use in the production of bispecific monoclonal antibodies

Bos, R. (author), van den Berg, E. (author), Nieuwenhuizen, W. (author), Gaubius Instituut TNO (author)

A method was investigated to transduce a specific drug resistance marker, coded on a bacterial plasmid construct, to a hybridoma cell line using electroporation. We tested the influence of several buffers and the form of the DNA on cell viability and stable transfection frequency. We found a tenfold higher stable transfection frequency using...

bookPart 1990